Clinical Trials Arena

Clinicaltrialsarena.com is part of a unique network of over 40 specialized B2B websites, reaching a vast global audience of key decision-makers, influencers, and thought leaders, totaling 55 million industry professionals annually. As a division of GlobalData, we leverage an extensive database of more than 1 billion data points related to companies, deals, projects, forecasts, and market trends. Our top-tier content is backed by this comprehensive data. With expertise across more than 80 global markets and a dedicated team of over 800 award-winning journalists, researchers, and analysts, we provide you with crucial insights that can significantly impact business success every day.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#279168

United States

#156794

Health/Biotechnology and Pharmaceuticals

#123

Traffic sources

Monthly visitors

Articles

GLP-1RAs show anti-cancer benefits beyond weight loss

3 days ago | clinicaltrialsarena.com | Abigail Beaney

A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting weight loss. The observational study (COM2-0186-22), presented during the European Congress on Obesity (ECO) taking place in Malaga, Spain between 11-14 May and published in the journal eClinicalMedicine, investigated first-generation GLP-1RAs Victoza (liraglutide) and Byetta (exenatide).
Novo Nordisk’s Sogroya matches Norditropin in children’s growth disorders

4 days ago | clinicaltrialsarena.com | Abigail Beaney

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin (somatropin) in children’s growth disorders in a Phase III trial. The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for gestational age (SGA), with Noonan syndrome (NS), or with idiopathic short stature (ISS)in the Phase III REAL8 basket study (NCT05330325).
Vir’s hepatitis B combo falls short in Phase II trial

4 days ago | clinicaltrialsarena.com | Abigail Beaney

Vir Biotechnology’s ‘functional cure’ combination therapy has failed to meet the efficacy endpoints in a Phase II trial in hepatitis B.
LumiThera shows improved AMD trial results

1 week ago | clinicaltrialsarena.com | Ross Law

LumiThera has released new topline data for its Valeda Light Delivery System treatment for slowing the progression of dry age-related macular degeneration (AMD). LumiThera’s Valeda became the first non-invasive approach for treating dry AMD following its authorisation by the US Food and Drug Administration (FDA) in November 2024.
Patient centricity and effective designs drive clinical trial success

1 week ago | clinicaltrialsarena.com | Irena Maragkou

The aim of the EU Clinical Trials Regulation (CTR) is to harmonise the clinical trial regulation process across 27 countries and have an 80-day approval timeline, stated Dr. Martine Dehlinger-Kremer, vice president of Scientific Affairs at global contract research organisation (CRO) ICON.
Dr. Falk Pharma’s PSC drug achieves endpoints in Phase III trial

1 week ago | clinicaltrialsarena.com | Abigail Beaney

Dr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing cholangitis (PSC). In the pivotal, Phase III NUC-5 trial, (NCT03872921), NCA showed statistical superiority over placebo in achieving the combined primary endpoints of partial normalisation of blood levels of a liver enzyme linked to PSC (alkaline phosphatase) and no progression of disease stage on histology.
Swiss biotech sector’s R&D investment grew in 2024 despite global trends

1 week ago | clinicaltrialsarena.com | Abigail Beaney

Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles. While many countries have seen a decline in investment in recent years, according to the Swiss Biotech Report 2025, investment into R&D in Switzerland reached SFr2.6bn ($3.16bn) in 2024, with private company investment accounting for SFr1.4bn of that. Apart from R&D investment, companies in Switzerland raised SFr2.5bn in funds in 2024, a 22% increase on 2023.
Putting patients and sites first is key to a seamless clinical trial transition

1 week ago | clinicaltrialsarena.com | Irena Maragkou

Sometimes trials can go off track and need rescuing, but that does not always have to mean a rescue from another CRO, says Suzanne McNally, Executive Director in Portfolio Management at contract research organisation (CRO) Parexel. While elaborating on the concept of ‘rescue’, she said: “It can also mean a transfer from one sponsor to another, or in the event of an asset purchase when one asset needs to be moved from one sponsor to another,” in addition to vendor transfers.
OCT Europe: Small and mid-sized sponsors demand smart and reliable partnerships

2 weeks ago | clinicaltrialsarena.com | Irena Maragkou

One of the key challenges in clinical trial operations today is maintaining a trustworthy and reliable relationship with partners, vendors, and sites, says Sarah Bischof, Head of Clinical Developments at invIOs, a private biotech company developing next-generation cancer therapies.
AstraZeneca’s triple-combo triumphs in two Phase III asthma trials

2 weeks ago | clinicaltrialsarena.com | Abigail Beaney

AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) has met the primary endpoints in two Phase III asthma trials.